Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death

Journal of Clinical Oncology

Volumn 17, Issue 3, 1999, Pages 1061-1070

  Dumontet, Charles ^a   Sikic, Branimir I ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUTHIONINE SULFOXIMINE; COLCHICINE; CRYPTOPHYCIN; CURACIN A; DISCODERMOLIDE; DNA; DOCETAXEL; DOLASTATIN; EPOTHILONE A; EPOTHILONE B; GLUTATHIONE; GLYCOPROTEIN P; MICROTUBULE ASSOCIATED PROTEIN; PACLITAXEL; TAXANE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; VINCA ALKALOID;

APOPTOSIS; CELL DEATH; DNA DAMAGE; DRUG MECHANISM; DRUG RESISTANCE; DRUG TRANSPORT; GENE; HUMAN; IMMUNOHISTOCHEMISTRY; MICROTUBULE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033052777     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.3.1061     Document Type: Review

References (116)

1. Hastie SB: Interactions of colchicine with tubulin. Pharmacol Ther 51:377-401, 1991
2. Malkinson FD: Colchicine: New uses for an old, old drug. Arch Dermatol 118:453-457, 1982
3. Borisy GG, Taylor EW: The mechanism of action of colchicine: Colchicine binding to sea urchin eggs and the mitotic apparatus. J Cell Biol 34:535-548, 1967
4. Little M, Seehaus T: Comparative analysis of tubulin sequences. Comp Biochem Physiol B Biochem Mol Biol 90:655-670, 1988
5. Abeloff MD: Vinorelbine (Navelbine) in the treatment of breast cancer: A summary. Semin Oncol 22:1-4, 41-44, 1995 (2 suppl 5)
6. Coltman CA Jr: Vinorelbine (Navelbine): A new agent for the treatment of non-small cell lung cancer: A summary. Semin Oncol 21:1-3, 1994
7. Devizzi L, Santoro A, Bonfante V, et al: Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 5:817-820, 1994
8. Dumontet C, Bastion Y, Felman P, et al: Long-term outcome and sequelae in aggressive lymphoma patients treated with the LNH-80 regimen. Ann Oncol 3:639-644, 1992
9. Jackson DV, Case LD, Pope EK, et al: Single agent vincristine by infusion in refractory multiple myeloma. J Clin Oncol 3:1508-1512, 1985
10. MacLennan IC, Cusick J: Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis: Medical Research Council Working Party on Leukaemia in Adults. Br J Cancer 52:153-158, 1985
11. Samson D, Gaminara E, Newland A, et al: Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 2:882-885, 1989
12. Jordan MA, Thrower D, Wilson L: Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res 51:2212-2222, 1991
13. Jordan MA, Toso RJ, Thrower D, et al: Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci U S A 90:9552-9556, 1993
14. Kirschner MW: Microtubule assembly and nucleation. Int Rev Cytol 54:1-71, 1978
15. Zheng Y, Jung MK, Oakley BR: Gamma-tubulin is present in Drosophila melanogaster and Homo sapiens and is associated with the centrosome. Cell 65:817-823, 1991
16. Tian G, Huang Y, Rommelaere H, et al: Pathway leading to correctly folded beta-tubulin. Cell 86:287-296, 1996
17. Sullivan KF, Cleveland DW: Identification of conserved isotype-defining variable region sequences for four vertebrate beta-tubulin polypeptide classes. Proc Natl Acad Sci U S A 83:4327-4331, 1986
18. Luduena RF: Multiple forms of tubulin: Different gene products and covalent modifications. Int Rev Cytol 178:207-275, 1998
19. Lewis SA, Gilmartin ME, Hall JL, et al: Three expressed sequences within the human beta-tubulin multigene family each define a distinct isotype. J Mol Biol 182:11-20, 1985
20. Villasante A, Wang D, Dobner P, et al: Six mouse alpha-tubulin mRNAs encode five distinct isotypes: Testis-specific expression of two sister genes. Mol Cell Biol 6:2409-2419, 1986
21. Cowan NJ, Lewis SA, Sarkar S, et al: Functional versatility of mammalian beta-tubulin isotypes, in Maccioni RB, Arechaga J (eds): The Cytoskeleton in Cell Differentiation and Development. New York, NY, ICSU Press, 1986, pp 157-166
22. Dobner PR, Kislauskis E, Wentworth BM, et al: Alternative 5' exons either provide or deny an initiator methionine codon to the same alpha-tubulin coding region. Nucleic Acids Res 15:199-218, 1987
23. Wilde CD, Crowther CE, Cripe TP, et al: Evidence that a human beta-tubulin pseudogene is derived from its corresponding mRNA. Nature 297:83-84, 1982
24. Gard DL, Kirschner MW: A polymer-dependent increase in phosphorylation of beta-tubulin accompanies differentiation of a mouse neuroblastoma cell line. J Cell Biol 100:764-774, 1985
25. Lewis SA, Gu W, Cowan NJ: Free intermingling of mammalian beta-tubulin isotypes among functionally distinct microtubules. Cell 49:539-548, 1987
26. Lopata MA, Cleveland DW: In vivo microtubules are copolymers of available beta-tubulin isotypes: Localization of each of six vertebrate beta-tubulin isotypes using polyclonal antibodies elicited by synthetic peptide antigens. J Cell Biol 105:1707-1720, 1987
27. Itoh TJ, Hotani H: Microtubule-stabilizing activity of microtubule-associated proteins is due to increase in frequency of rescue in dynamic instability: Shortening length decreases with binding of MAPs onto microtubules. Cell Struct Funct 19:279-290, 1994
28. Fellous A, Prasad V, Ohayon R, et al: Removal of the projection domain of microtubule-associated protein 2 alters its interaction with tubulin. J Protein Chem 13:381-391, 1994
29. Gonzalez M, Cambiazo V, Maccioni RB: Identification of a new microtubule-interacting protein Mip-90. Eur J Cell Biol 67:158-169, 1995
30. Cleveland DW, Hwo SY, Kirschner MW: Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol 116:207-225, 1977
31. Nguyen HL, Chari S, Gruber D, et al: Overexpression of full- or partial-length M1P4 stabilizes microtubules and alters cell growth. J Cell Sci 110:281-294, 1997
32. Mitchison T, Kirschner M: Dynamic instability of microtubule growth. Nature 312:237-242, 1984
33. Margolis RL, Wilson L: Opposite end assembly and disassembly of microtubules at steady state in vitro. Cell 13:1-8, 1978
34. Keith CH: Neunte elongation is blocked if microtubule polymerization is inhibited in PC12 cells. Cell Motil Cytoskeleton 17:95-105, 1990
35. Thatte SH, Bridges KR, Golan DE: Microtubule inhibitors differentially affect translational movement, cell surface expression and endocytosis of transferrin receptors in K562 cells. J Cell Physiol 160:345-357, 1994
36. Dhamodharan R, Jordan MA, Thrower D, et al: Vinblastine suppresses dynamics of individual microtubules in living interphase cells. Mol Biol Cell 6:1215-1229, 1995
37. Kadi A, Pichard V, Lehmann M, et al: Effect of microtubule disruption on cell adhesion and spreading. Biochem Biophys Res Commun 246:690-695, 1998
38. Belotti D, Vergani V, Drudis T, et al: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843-1849, 1996
39. Belotti D, Rieppi M, Nicoletti MI, et al: Paclitaxel (Taxol) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin Cancer Res 2:1725-1730, 1996
40. Wordeman L, Mitchison TJ: Dynamics of microtubule assembly in vivo, in Hyams JS, Lloyd CW (eds): Microtubules. New York, NY, Wiley-Liss, 1994, pp 287-301
41. Jordan MA, Wilson L: Microtubules and actin filaments: Dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10:123-130, 1998
42. Nogales E, Wolf SG, Downing KH: Structure of the alpha beta tubulin dimer by electron crystallography. Nature 391:199-203, 1998
43. Rao S, Krauss NE, Heerding JM, et al: 3′-(p-Azidobenzamido)-Taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem 269:3132-3134, 1994
44. Combeau C, Commercon A, Mioskowski C, et al: Predominant labeling of beta- over alpha-tubulin from porcine brain by a photoactivatable taxoid derivative. Biochemistry 33:6676-6683, 1994
45. Farrell KW, Wilson L: Tubulin-colchicine complexes differentially poison opposite microtubule ends. Biochemistry 23:3741-3748, 1984
46. Parness J, Horwitz SB: Taxol binds to polymerized tubulin in vitro. J Cell Biol 91:479-487, 1981
47. Derry WB, Wilson L, Jordan MA: Substoichiometric binding of Taxol suppresses microtubule dynamics. Biochem 34:2203-2211, 1995
48. Wilson L, Jordan MA: Microtubule dynamics: Taking aim at a moving target. Chem Biol 2:569-573, 1995
49. Dye RB, Fink SP, Williams RC Jr: Taxol-induced flexibility of microtubules and its reversal by MAP-2 and tau. J Biol Chem 268:6847-6850, 1993
50. Luduena RF, Roach MC, Trcka PP, et al: beta 2-Tubulin, a form of chordate brain tubulin with lesser reactivity toward an assembly-inhibiting sulfhydryl-directed cross-linking reagent. Biochemistry 21: 4787-4794, 1982
51. Falconer MM, Echeverri CJ, Brown DL: Differential sorting of beta-tubulin isotypes into colchicine-stable microtubules during neuronal and muscle differentiation of embryonal carcinoma cells. Cell Motil Cytoskeleton 21:313-325, 1992
52. Lobert S, Frankfurter A, Correia JJ: Binding of vinblastine to phosphocellulose-purified and a beta-class III tubulin: The role of nucleotides and beta-tubulin isotypes. Biochemistry 34:8050-8060, 1995
53. Laferriere NB, Brown DL: Effects of Taxol on the polymerization and posttranslational modification of class III beta-tubulin in P19 embryonal carcinoma cells. Biochem Cell Biol 73:687-694, 1995
54. Panda D, Miller HP, Banerjee A, et al: Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U S A 91:11358-11362, 1994
55. Derry WB, Wilson L, Khan IA, et al: Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry 36:3554-3562, 1997
56. Kartner N, Riordan JR, Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285-1288, 1983
57. Ling V: Charles F. Kettering Prize: P-glycoprotein and resistance to anticancer drugs. Cancer 69:2603-2609, 1992
58. Harker WG, Sikic BI: Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 45:4091-4096, 1985
59. Ueda K, Cardarelli C, Gottesman MM, et al: Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 84:3004-3008, 1987
60. Horwitz SB, Liao LL, Greenberger L, et al: Mode of action of Taxol and characterization of multidrug-resistant cell line resistant to Taxol, in Kessel D (ed): Resistance to Antineoplastic Drugs. Boca Raton, FL, CRC Press, 1989, pp 109-126
61. Cole SPC, Sparks KE, Fraser K, et al: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910, 1994
62. Lorico A, Rappa G, Flavell RA, et al: Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Res 56:5351-5355, 1996
63. Samuels BL, Hollis DR, Rosner GL, et al: Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: A Cancer and Leukemia Group B study. Clin Cancer Res 3:1977-1984, 1997
64. Liebmann JE, Hahn SM, Cook JA, et al: Glutathione depletion by L-buthionine sulfoximine antagonizes Taxol cytotoxicity. Cancer Res 53:2066-2070, 1993
65. Banerjee A, Jordan MA, Luduena RF: Interaction of reduced glutathione with bovine brain tubulin. Biochem Biophys Res Commun 128:506-512, 1985
66. Cabral F, Barlow SB: Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J 3:1593-1599, 1989
67. Minotti AM, Barlow SB, Cabrai F: Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 266:3987-3994, 1991
68. Boggs BA, Gonzalez-Garay ML, O'Brien WE, et al: Mechanisms of cellular resistance to drugs that target microtubules. Cell Pharmacol 1:64-66, 1993 (suppl 1)
69. Schibler MJ, Barlow SB, Cabral F: Elimination of permeability mutants from selections for drug resistance in mammalian cells. FASEB J 3:163-168, 1989
70. Jordan MA, Thrower D, Wilson L: Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles: Implications for the role of microtubule dynamics in mitosis. J Cell Sci 102:401-416, 1992 (part 3)
71. Aoe K, Ueoka H, Kiura K, et al: Synergistic effect of docetaxel and vinorelbine against in vitro growth of a human small cell lung cancer cell line. Presented at Am Assoc Cancer Res, Washington, DC, 1996
72. Photiou A, Shah P, Leong LK, et al: In vitro synergy of paclitaxel (Taxol) and vinorelbine (Navelbine) against human melanoma cell lines. Eur J Cancer 33:463-470, 1997
73. Knick VC, Eberwein DJ, Miller CG: Vinorelbine tartrate and paclitaxel combinations: Enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 87:1072-1077, 1995
74. Viallet J, Laberge F, Martins H, et al: Docetaxel alternating with cisplatin and vinorelbine: Early evidence of additive activity in a phase II trial of non small cell lung cancer. Proc Am Soc Clin Oncol 15:375, 1996
75. Miller VA: Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: Preliminary results of a phase I/II trial. Semin Oncol 24:514-15-514-17, 1997 (4 suppl 14)
76. Dieras V, Fumoleau P, Kalla S, et al: Docetaxel in combination with doxorubicin or vinorelbine. Eur J Cancer 33:S20-S22, 1997 (suppl 7)
77. Monnier A, Riviere A, Douillard JY, et al: Phase II study of docetaxel and vinorelbine in chemotherapy naive patients with advanced non small cell lung carcinoma. Proc Am Soc Clin Oncol 15:378, 1996
78. Parimoo D, Jeffers S, Muggia FM: Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst 88:1079-1080, 1996
79. Kourousis C, Kakolyris S, Androulakis N, et al: Salvage chemotherapy with paclitaxel, vinorelbine and cisplatin (PVC) in anthracycline-resistant advanced breast cancer. Am J Clin Oncol 21:226-232, 1998
80. Cabral F, Sobel ME, Gottesman MM: CHO mutants resistant to colchicine, Colcemid or griseofulvin have an altered beta-tubulin. Cell 20:29-36, 1980
81. Ohta S, Nishio K, Ohmori T, et al: Resistance to tubulin interacting agents Taxol and vinca alkaloids, in Miyazaki T, Takaku F, Sakurada K (eds): The Mechanism of and New Approach to Drug Resistance of Cancer Cells. New York, NY, Elsevier Science, 1993, pp 209-212
82. Jaffrezou JP, Dumontet C, Derry WB, et al: Novel mechanism of resistance to paclitaxel (Taxol) in human leukemia K562 cells by combined selection with PSC 833. Oncol Res 7:517-527, 1995
83. Dumontet C, Jaffrezou JP, Tsuchiya E, et al: Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Elec J Oncol 2:44-54, 1998
84. Cabral F, Abraham I, Gottesman MM: Isolation of a Taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin. Proc Natl Acad Sci U S A 78:4388-4391, 1981
85. Kavallaris M, Kuo DYS, Burkhart CA, et al: Taxol resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100:1282-1293, 1997
86. Haber M, Burkhart CA, Regl DR, et al: Altered expression of Mβ2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of Taxol resistance. J Biol Chem 270:31269-31275, 1995
87. Ranganathan S, Dexter DW, Benetatos CA, et al: Increase of beta III- and beta IVa-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 56:2584-2589, 1996
88. Giannakakou P, Sackett DL, Kang YK, et al: Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118-17125, 1997
89. Burkhart CA, Kavallaris M, Horwitz SB: Inducible expression of the class II beta-tubulin isotype in murine fibroblast cells. Presented at Am Assoc Cancer Res, New Orleans, LA, 1998 (abstr 1295)
90. Jordan MA, Wendell KL, Gardiner S, et al: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56:816-825, 1996
91. Lehrich RW, Forrest JN: Protein kinase C theta is associated with the mitotic apparatus in primary cell cultures of the shark rectal gland. J Biol Chem 269:32446-32450, 1994
92. Ookata K, Hisanaga S, Okumura E, et al: Association of p34cdc2/cyclin B complex with microtubules in starfish oocytes. J Cell Sci 105:873-881, 1993
93. Alexandrova N, Niklinski J, Bliskovsky V, et al: The N-terminal portion of c-myc associates with alpha-tubulin and microtubules in vivo and in vitro. Mol Cell Biol 15:5188-5195, 1995
94. Sumantran VN, Ealovega MW, Nunez G, et al: Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55:2507-2510, 1995
95. Tang C, Willingham MC, Reed JC, et al: High levels of p26BCL-2 oncoprotein retard Taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8:1960-1969, 1994
96. Murphy M, Hinmann A, Levine AJ: Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev 10:2971-2980, 1996
97. Zhang CC, Yang JM, White E, et al: The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 16:1617-1624, 1998
98. Sangrajrang S, Denoulet P, Millot G, et al: Estramustine resistance correlates with tau overexpression in human prostatic carcinoma cells. Int J Cancer 77:626-631, 1998
99. Hawkins DS, Demers GW, Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56:892-898, 1996
100. Wahl AF, Donaldson KL, Fairchild C, et al: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72-79, 1996
101. Woods CM, Zhu J, McQueney PA, et al: Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1:506-526, 1995
102. Blagosklonny MV, Schulte TW, Nguyen P, et al: Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res 55:4623-4626, 1995
103. Tishler RB, Lamppu DM, Park S, et al: Microtubule-active drugs Taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res 55:6021-6025, 1995
104. Liu QY, Stein CA: Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-XL and bak expression. Clin Cancer Res 3:2039-2046, 1997
105. Moos PJ, Fitzpatrick FA: Taxane-mediated gene induction is independent of microtubule stabilization: Induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci U S A 95:3896-3901, 1998
106. Ciomei M, Pastori W, Biasoli G, et al: Alkylating Taxols able to bind irreversibly to the tubulin are active on Taxol-resistant cell lines. Presented at Am Assoc Cancer Res, Washington, DC, 1996
107. Laing N, Dahllof B, Hartley-Asp B, et al: Interaction of estramustine with tubulin isotypes. Biochemistry 36:871-878, 1997
108. Speicher LA, Barone L, Tew KD: Combined antimicrotubule activity of estramustine and Taxol in human prostatic carcinoma cell lines. Cancer Res 52:4433-4440, 1992
109. Balachandran R, ter Haar E, Longley RE, et al: Effects of the novel microtubule stabilizing agent discodermolide on the microtubule network, nuclear morphology and viability of breast cancer cells. Presented at Am Assoc Cancer Res, Washington, DC, 1996
110. ter Haar E, Kowalski RJ, Hamel E, et al: Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than Taxol. Biochemistry 35:243-250, 1996
111. Bollag DM, McQueney PA, Zhu J, et al: Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res 55:2325-2333, 1995
112. Kowalski RJ, Giannakakou P, ter Haar E, et al: Comparison of structurally novel microtubule polymerizing agents, discodermolide and epothilone A/B, with paclitaxel. Presented at Am Assoc Cancer Res, Washington, DC, 1996
113. Panda D, Himes RH, Moore RE, et al: Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1. Biochemistry 36:12948-12953, 1997
114. Bai R, Taylor GF, Schmidt JM, et al: Interaction of dolastatin 10 with tubulin: Induction of aggregation and binding and dissociation reactions. Mol Pharmacol 47:965-976, 1995
115. Hamel E: Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin 1, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 55:31-51, 1992
116. Smith CD, Zhang X, Mooberry SL, et al: Cryptophycin: A new antimicrotubule agent active against drug-resistant cells. Cancer Res 54:3779-3784, 1994